Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.
We investigated the possibility of using a pharmacologic agent to modulate viral gene expression to target radiotherapy to tumor tissue. In a mouse xenograft model, we had previously shown targeting of [(125)I]2'-fluoro-2'-deoxy-beta-D-5-iodouracil-arabinofuranoside ([(125)I]FIAU) to tumors engineered to express the Epstein-Barr virus thymidine kinase (EBV-TK). Here we extend those results to targeting of a therapeutic radiopharmaceutical [(131)I]FIAU to slow or stop tumor growth or to achieve tumor regression. These outcomes were achieved in xenografts with tumors that constitutively expressed the EBV-TK. With naturally infected EBV tumor cell lines (Burkitt's lymphoma and gastric carcinoma), activation of viral gene expression by pretreatment with bortezomib was required. Marked changes in tumor growth could also be achieved in naturally infected Kaposi's sarcoma herpesvirus tumors after pretreatment with bortezomib. Bortezomib-induced enzyme-targeted radiation therapy illustrates the possibility of pharmacologically modulating tumor gene expression to result in targeted radiotherapy.
Fu
De-Xue
DX
Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA.
Tanhehco
Yvette
Y
Chen
Jianmeng
J
Foss
Catherine A
CA
Fox
James J
JJ
Chong
Ja-Mun
JM
Hobbs
Robert F
RF
Fukayama
Masashi
M
Sgouros
George
G
Kowalski
Jeanne
J
Pomper
Martin G
MG
Ambinder
Richard F
RF
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D002051:Burkitt Lymphoma / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D006566:Herpesviridae Infections / Q000532:radiotherapy; D004854:Herpesvirus 4, Human / Q000201:enzymology; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D011719:Pyrazines / Q000494:pharmacology*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D012514:Sarcoma, Kaposi / Q000532:radiotherapy; D013274:Stomach Neoplasms / Q000532:radiotherapy*; D013937:Thymidine Kinase / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D007457:Iodine Radioisotopes; D011719:Pyrazines; D019275:Radiopharmaceuticals; D001086:Arabinofuranosyluracil; C043457:fialuridine; D000069286:Bortezomib; D013937:Thymidine Kinase
N Engl J Med. 1995 Oct 26;333(17):1099-105
7565947
Mol Imaging Biol. 2007 May-Jun;9(3):110-6
17294333
J Nucl Med. 2003 Feb;44(2):260-8
12571219
Antimicrob Agents Chemother. 2001 Jul;45(7):2082-91
11408227
N Engl J Med. 2005 Feb 3;352(5):441-9
15689582
J Nucl Med. 2001 Mar;42(3):467-75
11337525
Gene Ther. 2005 Jul;12(13):1033-41
15789060
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
J Virol. 2001 May;75(10):4482-9
11312318
J Nucl Med. 2007 Jan;48(1):150-7
17204712
J Virol. 2002 Jul;76(13):6825-31
12050395
J Biol Chem. 2001 Nov 2;276(44):40847-57
11526116
Cancer Res. 2000 Oct 15;60(20):5781-8
11059774
Int J Cancer. 2007 Jan 1;120(1):60-6
17058198
Clin Cancer Res. 2007 Mar 1;13(5):1453-8
17332288
J Clin Invest. 1995 Feb;95(2):555-63
7860738
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3592-7
8622980
Q J Nucl Med. 1999 Jun;43(2):163-9
10429512
PLoS One. 2007 Oct 10;2(10):e1007
17925855
Cancer Res. 1992 Oct 1;52(19):5144-53
1327501
Cancer Res. 1995 Dec 15;55(24):6126-32
8521403
J Virol. 2003 Sep;77(17):9590-612
12915572
Eur J Nucl Med. 2000 Mar;27(3):283-91
10774880
Nucl Med Commun. 2003 Sep;24(9):951-7
12960593
J Virol. 2004 Feb;78(4):1893-902
14747554
Cancer. 2007 May 1;109(9):1804-10
17380530
Mol Pathol. 2000 Oct;53(5):255-61
11091849
BMC Cancer. 2005 Apr 02;5:32
15804364
J Virol. 2003 Jan;77(2):1481-500
12502863
Blood. 2007 Mar 15;109(6):2571-8
17119113